AccessibilityHelpAbout Us
Eupraxia Pharmaceuticals logo

Eupraxia Pharmaceuticals(NASDAQ) EPRX

Market Cap$527.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+187%
5 Year+270%
1 Year+39%
1 Month+8%
$8.03
-1.59%
-0.13Today
After hours$8.02-$0.01 (-0.13%)
Eupraxia Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 8.012026-09-25
Eupraxia Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.64%USD 8.582026-09-18
1 month+7.81%USD 7.432026-08-26
3 month+21.36%USD 6.602026-06-26
Year to date+6.09%USD 7.552025-12-31
1 year+39.06%USD 5.762025-09-25
3 year+45.11%USD 5.522023-09-26
5 year+270.1%USD 2.162021-09-22
Since inception+187.2%USD 2.792021-08-03

Eupraxia Pharmaceuticals Financials at a Glance

Market Cap

$527.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$50.22M

EPS (TTM)

-$0.98

P/E Ratio

-8.14

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$8.03

Volume

1,313,306.081

Open

$8.19

Previous Close

$8.01

Daily Range

$7.86 - $8.30

52-Week Range

$5.25 - $9.32

Estimated Earnings Date

Nov 3, 2026

EPRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies for unmet medical needs. Utilizing its proprietary Diffusphere technology, the company optimizes drug delivery across various therapeutic areas, including knee osteoarthritis and eosinophilic esophagitis.

Products and Services
  • EP-104IAR: Phase III trial for knee osteoarthritis treatment
  • EP-104GI: Phase II trial for eosinophilic esophagitis
  • EP-104: Preclinical studies for gastrointestinal tract conditions
Growth Outlook
  • Strong pipeline with multiple products in advanced clinical trials
  • Significant market potential in underserved therapeutic areas
  • Proprietary technology enhances competitive positioning
Financial Highlights
  • Cash and short-term investments of $133.4 million as of June 30, 2026
  • Operating expenses of $18.1 million in Q2 2026, reflecting ongoing R&D investments
  • Net income of -$14.5 million for Q2 2026, consistent with growth phase
Eupraxia Pharmaceuticals Inc. is positioned in the biotechnology sector, focusing on innovative solutions for significant health challenges. The company's advanced clinical trials and proprietary technology provide a strong foundation for future growth. With substantial cash reserves, Eupraxia is well-equipped to continue its research and development efforts, aiming to bring transformative therapies to market. The financial data indicates a commitment to innovation, despite current operating losses typical for companies in the growth phase. Investors may find the company's strategic focus and robust pipeline appealing as it navigates the complexities of the biotechnology landscape.
AI Generated • Sep 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

49

CEO

James A. Helliwell, MD

Website

www.eupraxiapharma.com

Headquarters

Victoria, BC V8R 5G4, CA

EPRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-45.29%

Return on Capital

-46.76%

Return on Assets

-35.72%

Earnings Yield

-12.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$527.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.91M

Volume

1.31M

Avg. Volume

427.46K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$57.11M

EBITDA

-$49.91M

Operating Cash Flow

-$35.86M

Capital Expenditure

-$731.36K

Free Cash Flow

-$36.59M

Cash & ST Invst.

$133.40M

Total Debt

$1.84M

Eupraxia Pharmaceuticals Performance Analysis

Eupraxia Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Eupraxia Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Eupraxia Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.96-25.5%
20232023-12-31USD -1.1721.9%
20242024-12-31USD -0.75-35.7%
20252025-12-31USD -1.0336.9%
Eupraxia Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.8%
Q42025-12-31-78.9%
Q12026-03-3132.4%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$527.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.77M

N/A

Employees

49

N/A

Net Income

-$14.49M

-65.8%

EBITDA

-$14.33M

-64.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$133.40M

+574.9%

Total Debt

$1.84M

+5145.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.68M

N/A

Short Term Debt

$159.57K

+355.1%

Return on Assets

-35.72%

N/A

Return on Invested Capital

-43.18%

N/A

Free Cash Flow

-$12.92M

-52.3%

Operating Cash Flow

-$12.75M

-53.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNFTGenfit S.A.
$8.95+4.07%
OBIOOrchestra BioMed Holdings, Inc.
$5.95+0.00%
RNACCartesian Therapeutics, Inc.
$7.41-2.76%
TARAProtara Therapeutics, Inc.
$3.28-2.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About EPRX

What is the current price of Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals is trading at $8.01 per share.

What is the 52-week range for Eupraxia Pharmaceuticals?

Over the past 52 weeks, Eupraxia Pharmaceuticals has traded between $5.25 and $9.32.

How much debt does Eupraxia Pharmaceuticals have?

As of the most recent reporting period, Eupraxia Pharmaceuticals reported total debt of $1.84M.

How much cash does Eupraxia Pharmaceuticals have on hand?

Eupraxia Pharmaceuticals reported $52.43M in cash and cash equivalents in its most recent financial results.

What is Eupraxia Pharmaceuticals’s dividend yield?

Eupraxia Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services